Medizentrum Essen-Borbeck

Essen 45355

4 studies enrolling now · 24 studies all time

What they study most

Atherosclerotic Cardiovascular Disease (ASCVD), Atrial Fibrillation, COVID-19, Cardiovascular Disease, Chronic Obstructive Pulmonary Disease, Diabetes, Type 2, Elevated Lp(a), Gout, Gout Flare, Heart Failure, Hypertension, Hyperuricemia

Studies at this site

• A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes — Recruiting now
• A Study to Evaluate the Long-Term Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease (COPD) — Recruiting now
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes — Recruiting now
• A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes — Recruiting now
• A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity — Recruiting now
• A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity — Running, not enrolling
• A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) — Running, not enrolling
• Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity — Running, not enrolling
• A Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) — Running, not enrolling
• A Study of Milvexian Versus Apixaban in Participants With Atrial Fibrillation — Running, not enrolling
• A Master Protocol for Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight: (ATTAIN-Hypertension Screening) — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL1 — Running, not enrolling
• A Master Protocol Study of Orforglipron (LY3502970) in Participants With Hypertension and Obesity or Overweight (ATTAIN-Hypertension) GZL2 — Running, not enrolling
• A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes — Running, not enrolling
• Study to Describe the Safety, Tolerability, Immunogenicity, and Efficacy of RNA Vaccine Candidates Against COVID-19 in Healthy Individuals — Completed
• A Study to Evaluate the Efficacy and Safety of Astegolimab in Participants With Chronic Obstructive Pulmonary Disease — Completed
• A Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity — Running, not enrolling
• A Study of mRNA-1010 Compared With a Licensed Influenza Vaccine in Adults ≥50 Years of Age — Completed
• Tigulixostat, Phase 3 Study, Allopurinol Controlled in Gout Patients — Completed
• Efficacy and Safety of PQ Grass in Subjects With Seasonal Allergic Rhinitis and/or Rhinoconjunctivitis Induced by Grass Pollen — Completed
• A Study of mRNA-1010 Seasonal Influenza Vaccine in Adults 50 Years Old and Older — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early